




## CV Template of KATRD International Conference 2021

<b>Name</b>	Herbert Loong			
<b>First Name</b>	Herbert	<b>Last Name</b>	Loong	
<b>Country</b>	Hong Kong			
<b>Organization</b>	The Chinese University of Hong Kong			
<b>Current Position</b>	Clinical Associate Professor			

### Educational Background

Faculty of Medicine, The University of Hong Kong, Hong Kong	MBBS (with Distinction in Surgery)	06/2003	Medicine & Surgery
Membership Examination, Royal Colleges of Physicians, United Kingdom	MRCP(UK)	03/2006	Internal Medicine
Fellow (By Examination), Hong Kong College of Physicians, Hong Kong	FHKCP	06/2010	Medical Oncology
Fellow (By Examination), Hong Kong Academy of Medicine, Hong Kong	FHKAM (Medicine)	10/2010	Internal Medicine
Clinical Research Fellowship, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Canada	--	2013	Fellowship in Drug Development
Postgraduate Diploma in Molecular & Diagnostic Pathology, The University of Hong Kong	PDipMDPath	10/2016	Molecular & Diagnostic Pathology
Fellow, Royal College of Physicians of Edinburgh, United Kingdom	FRCP Edin	7/2018	Internal Medicine

### Professional Experiences

I am an academic medical oncologist with a clinical and research interest in oncology drug development, translational therapeutics and medical education. I have completed a Clinical Research Fellowship in Drug Development at the Princess Margaret Cancer Centre in Toronto, Canada and have established a firm interest in clinical development of novel therapeutics, especially pertaining to thoracic oncology, sarcoma medical oncology and neuro-oncology. My overriding aim in the first few years as an academic staff is to improve the treatment outcomes and prognoses of patients – both individually and, through my interests in drug development, clinical trials and medical education.



## Professional Organizations

Committee Member, American Society of Clinical Oncology (ASCO)  
Committee Member, International Association for the Study of Lung Cancer (IASLC)  
European Society for Medical Oncology (ESMO)  
Connective Tissue Oncology Society (CTOS)  
Hong Kong Cancer Therapy Society

## Main Scientific Publications

1. **Loong HH**, Wong AM, Chan DTM, Cheung MSH, Chow C, Ding X, Chan AKY, Johnston PA, Lau JYW, Poon WS, Wong N. Patient-derived tumor organoid predicts drugs response in glioblastoma: a step forward in personalized cancer therapy? J Clin Neurosci 2020. (Accepted and pending citation assignment)
2. Zhu VW, Lin YT, Kim DW, **Loong HH**, Nagasaka M, Tao H, Ang YLE, Ock CY, Tchekmedyan N, Ou SHI, Syn NL, Reungwetwattana T, Lin CC, Soo RA. An international real-world analysis of efficacy and safety of lorlatinib via early or expanded access programs in patients with TKI-refractory ALK+ or ROS1 NSCLC. J Thorac Oncol, 2020.
3. Y, Tse KY, Lee HHY, Chow KL, Tsang HW, Wong RWC, Cheung ETY, Cheuk W, Lee VWK, Chan WK, Wong AST, **Loong HHF**, Chan KKL, Ngan HYS, Cheung ANY, Ip PPC. Predictive biomarkers and tumor microenvironment in female genital melanomas: a multi-institutional study of 55 cases. Mod Pathol. 2020 Jan;33(1):138-52. PubMed PMID: 31383965. Epub 2019/08/07.
4. **Loong HH**, Wong CKH, Leung LKS, Tan SC, Jen J, Lee MYK, Aguiar-Ibanez R, Wang J. Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong. Cost Eff Resour Alloc. 2020;18:2. PubMed PMID: 31969794. Epub 2020/01/24.
5. Heng M, Gupta A, Chung PW, Healey JH, Vaynrub M, Rose PS, Houdek MT, Lin PP, Bishop AJ, Hornicek FJ, Chen YL, Lozano-Calderon S, Holt GE, Han I, Biau D, Niu XH, Bernthal NM, Ferguson PC, Wunder JS, Ueda T, Kakunaga S, Kawai A, Sugiura H, Kidani T, Kunisasa T, Ozaki T, Ae K, Nagano A, Ohno T, Hiraoka K, Yamamoto N, Tsuchiya H, Matsumoto Y, Yanagawa T, Nakayama R, Morioka H, Kubo T, Simose S, Yamagami Y, Yamamoto T, Kawasaki M, Torigoe T, Yazawa Y, Akiyama T, Gokita T, Manabe J, Kaya M, Emori M, Nakamura T, Matsumine A, Sugihara S, Yokouchi M, Komiya S, Suehara Y, Takagi T, Kawamoto T, Wasa J, Yonemoto T, Ishii T, Baba I, Hoshi M, Hamada K, Naka N, Sotobori T, Araki N, Okuma T, Goto T, Kobayashi H, Kawano H, Hosaka M, Futani H, Hiraga H, Nishida Y, Griffin A, Razak ARA, Shultz DB, Catton C, Robinson S, Patel SR, Lewis VO, Guadagnolo BA, DeLaney T, Wang HT, Raskin K, Callan AK, Henshaw R, Isler M, Mottard S, Chen WM, Traub F, Chen TWW, Turcotte RE, Davidson D, Tunn PU, **Loong H**, Ghert M, Werier J, Clarkson P, Abraham JA, Oncology JM, Int STO. The role of chemotherapy and radiotherapy in localized extraskeletal osteosarcoma. European Journal of Cancer. 2020 Jan;125:130-41. PubMed PMID: WOS:000505199600015.
6. Felip E, de Braud FG, Maur M, **Loong HH**, Shaw AT, Vansteenkiste JF, John T, Liu G, Lolkema MP, Selvaggi G, Giannone V, Cazorla P, Baum J, Balbin OA, Wang LV, Lau YY, Scott JW, Tan



- DS. Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study. *J Thorac Oncol.* 2020 Mar;15(3):392-403. PubMed PMID: 31634667. Epub 2019/10/22.
7. Doebele RC, Drlon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, **Loong HH**, Buchschacher GL, Jr., Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD, trial i. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. *Lancet Oncol.* 2020 Feb;21(2):271-82. PubMed PMID: 31838007. Epub 2019/12/16.
8. Woo PYM, Lam TC, Pu JKS, Li LF, Leung RCY, Ho JMK, Zhung JTF, Wong B, Chan TSK, **Loong HHF**, Ng HK. Regression of BRAF (V600E) mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases. *Oncotarget.* 2019 Jun 4;10(38):3818-26. PubMed PMID: 31217909. Pubmed Central PMCID: PMC6557198. Epub 2019/06/21.
9. Veitch Z, Zer A, **Loong H**, Salah S, Masood M, Gupta A, Bradbury PA, Hogg D, Wong A, Kandel R, Charames GS, Abdul Razak AR. A phase II study of ENMD-2076 in advanced soft tissue sarcoma (STS). *Sci Rep.* 2019 May 14;9(1):7390. PubMed PMID: 31089155. Pubmed Central PMCID: PMC6517396. Epub 2019/05/16.
10. **Loong HH**, Wong CKH, Leung LKS, Dhankhar P, Insinga RP, Chandwani S, Hsu DC, Lee MYK, Huang M, Pellissier J, Rai A, Achra M, Tan SC. Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong. *Pharmacoecon Open.* 2019 Sep 17. PubMed PMID: 31531842. Epub 2019/09/19.